AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Worth Watching Stock

Share

Its down 0.25, from 1 in 2017Q1. The value of the investment in AcelRx Pharmaceuticals, Inc. went from $254,000 to $152,000 a change of 40.2% quarter to quarter. 11 funds opened positions while 13 raised stakes.

General Motors Company was covered by a number of analysts recently, 1 rated the stock as Buy, 3 rated Outperform, 2 rated Hold, 0 gave an Underperform and 0 rated sell. National Bank & Trust Of America De invested in 0% or 14,964 shares.

Analyzing recent insider trading activity at AcelRx Pharmaceuticals, Inc. Ing Groep Nv holds 39,000 shares. Bank of New York Mellon Corp lifted its holdings in shares of AcelRx Pharmaceuticals by 6.6% during the 1st quarter. Wells Fargo & Communication Mn stated it has 26,717 shares. Hawk Ridge Management Llc acquired 61,000 shares as Caesarstone Ltd (CSTE)'s stock rose 15.69%. 10,000 are owned by Drw Secs Limited Company. The insider now holds 80,354 shares of AcelRx Pharmaceuticals, Inc. AcelRx Pharmaceuticals has a 1-year low of $1.95 and a 1-year high of $5.75. Cowen and Company restated a "hold" rating on shares of AcelRx Pharmaceuticals in a report on Tuesday, August 1st. The 1-year high was reported on Oct, 12 by Barchart.com.

Mark G. Edwards, Director purchased $14,800 worth of shares at a price of $2.96 on Thursday the 24th. It is trading at $5.50 which is well above $3.69, the stock's 50 day moving average and significantly higher than the 200 day moving average of $2.95. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. Volume is the basic fuel of the market since stocks move up or down in price only when shares are trading hands. Analysts expect next quarter's EPS will be $-0.25 with next year's EPS projected to be $-0.84. Analysts are forecasting earnings of $-0.27 on a per share basis this quarter. Therefore 75% are positive. $8.42's average target is 274.22% above currents $2.25 stock price. A total number of 6 analysts provided estimations over revenues. The median estimate represents a 34.62% increase from the last price of 5.20. (NASDAQ:ACRX) is a good way of gaining insight into the stock's performance.

Presently, Acelrx Pharmaceutica (ACRX) has a 14-day Commodity Channel Index (CCI) of -242.93. Chardan Capital Markets initiated the stock with "Buy" rating in Wednesday, April 6 report. The firm recorded a rise in short interest from August 31, 2017 to September 15, 2017 of 19.79%. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal. A stock that maintains a relatively stable price has low volatility. The normal reading of a stock will fall in the range of 30 to 70. RBC Capital Markets has "Buy" rating and $6.0 target. Susquehanna Int Grp Inc Llp holds 0% of its portfolio in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) for 167,089 shares. (ACRX) in trading session dated October 02, 2017.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The third largest holder is Palo Alto Investors, Llc, which now holds $5.37 million worth of this stock and that ownership represents almost 2.08% of its market capitalization. The Business's product candidate pipeline also includes ARX-03, which is a single, fixed-dose, combination drug product created to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.

Share